Masimo Files Investor Presentation Highlighting Strategic Initiatives To Deliver Robust Growth And Margin Expansion; Politan Is Making A Bid For Control Without Paying A Premium Or Articulating A Clear Plan Seeking To Replace Masimo Founder, Chairman...
Masimo Files Investor Presentation Highlighting Strategic Initiatives To Deliver Robust Growth And Margin Expansion; Politan Is Making A Bid For Control Without Paying A Premium Or Articulating A Clear Plan Seeking To Replace Masimo Founder, Chairman...
Masimo Files Investor Presentation Highlighting Strategic Initiatives To Deliver Robust Growth And Margin Expansion; Politan Is Making A Bid For Control Without Paying A Premium Or Articulating A Clear Plan Seeking To Replace Masimo Founder, Chairman And CEO Joe Kiani With Politan Nominees
麦斯莫医疗提交投资者演示文稿，重点介绍了旨在提供强劲增长和利润率扩张的战略举措。Politan提出的控制标的的报价未提出明确计划，也未支付溢价金，并寻求取代麦斯莫医疗的创始人、董事长和CEO Joe Kiani。
Masimo's Strategy Capitalizes on Innovation to Enhance Growth and Create Value for All Stockholders
麦斯莫医疗的策略是利用创新提高增长，为所有股东创造价值。
Politan is Making a Bid for Control Without Paying a Premium or Articulating a Clear Plan
Politan以不支付溢价或明确计划来竞购控制权。
Politan is Seeking to Replace Masimo Founder, Chairman and CEO Joe Kiani with Inferior Politan Nominees
Politan试图用次等的Politan提名者取代麦斯莫医疗的创始人、董事长和CEO Joe Kiani。
Politan's Actions are a Threat to Stockholder Value
Politan的行动对股东价值构成威胁。
Masimo Has a Better Plan and Better Nominees
麦斯莫医疗有更好的计划和提名者。
Strongly Encourages Stockholders to Vote FOR Joe Kiani and Christopher Chavez on the GOLD Proxy Card
强烈建议股东在代理卡上投票支持Joe Kiani和Christopher Chavez。黄金请访问ProtectMasimosFuture.com以了解更多信息。
Visit ProtectMasimosFuture.com for More Information
访问 ProtectMasimosFuture.com 了解更多信息
Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI) today filed an investor presentation with the U.S. Securities and Exchange Commission in connection with its Annual Meeting of Stockholders to be held on July 25, 2024. The presentation lays out in detail:
麦斯莫医疗公司（“麦斯莫”或“公司”）（纳斯达克证券交易所：MASI）今天在美国证券交易委员会提交投资者演示文稿，以应对于2024年7月25日举行的其股东年会有关的问题。该演示文稿详细介绍：
- The Company's robust track record of innovation, led by Masimo Founder, Chairman and CEO Joe Kiani, that supports Masimo's longstanding valuation premium to industry peers;
- Masimo's strategic initiatives for sustained growth and margin expansion that are expected to more than double adjusted EPS to ~$8 by 2029; and
- The Company's belief that Politan's value-destructive agenda to oust Mr. Kiani and take control of Masimo without paying a premium or articulating an exercisable plan poses a significant risk to the value of the Company.
- 由麦斯莫医疗的创始人、董事长和CEO Joe Kiani领导的创新贡献，支持了麦斯莫医疗长期以来高于行业同行的估值溢价；
- 麦斯莫医疗为持续增长和利润率扩张制定的战略举措预计将在2029年将调整后的每股收益翻番至约8美元；以及
- 公司相信，Politan的破坏价值议程，即未支付溢价金或提出可行计划而将Kiani先生赶下台并控制麦斯莫医疗，对公司价值构成了重大风险。
To safeguard stockholders' investments and ensure continued value creation, the Board strongly recommends that stockholders vote FOR Masimo's highly qualified director nominees, Joe Kiani and Christopher Chavez.
为保障股东投资并确保持续创造价值，董事会强烈建议股东投票支持麦斯莫医疗的高素质董事任命提名者，即Joe Kiani和Christopher Chavez。
The presentation is available here.
此演示文稿可在此处查看。